Cargando…

Pregnancy Outcomes in HIV-Infected Women Receiving Long-Term Isoniazid Prophylaxis for Tuberculosis and Antiretroviral Therapy

Objective. While 6- to 12-month courses of isoniazid for tuberculosis prevention are considered safe in pregnant women, the effects of longer-term isoniazid prophylaxis or isoniazid in combination with antiretroviral therapy (ART) are not established in human-immunodeficiency-virus-(HIV-) infected w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taylor, Allan W., Mosimaneotsile, Barudi, Mathebula, Unami, Mathoma, Anikie, Moathlodi, Ritah, Theebetsile, Irene, Samandari, Taraz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3606726/ https://www.ncbi.nlm.nih.gov/pubmed/23533318 http://dx.doi.org/10.1155/2013/195637

Ejemplares similares

Risk Factors for Non-Adherence and Loss to Follow-Up in a Three-Year Clinical Trial in Botswana
por: Gust, Deborah A., et al.
Publicado: (2011)

Repeated Assessments of Informed Consent Comprehension among HIV-Infected Participants of a Three-Year Clinical Trial in Botswana
por: Chaisson, Lelia H., et al.
Publicado: (2011)

Effect of tuberculosis screening and retention interventions on early antiretroviral therapy mortality in Botswana: a stepped-wedge cluster randomized trial
por: Auld, Andrew F., et al.
Publicado: (2020)

Tuberculosis treatment outcomes among people living with HIV diagnosed using Xpert MTB/RIF versus sputum-smear microscopy in Botswana: a stepped-wedge cluster randomised trial
por: Agizew, Tefera, et al.
Publicado: (2019)

Outcomes of HIV-positive patients with non-tuberculous mycobacteria positive culture who received anti-tuberculous treatment in Botswana: Implications of using diagnostic algorithms without non-tuberculous mycobacteria
por: Agizew, Tefera, et al.
Publicado: (2020)

Higher-than-expected prevalence of non-tuberculous mycobacteria in HIV setting in Botswana: Implications for diagnostic algorithms using Xpert MTB/RIF assay
por: Agizew, Tefera, et al.
Publicado: (2017)

Peripheral clinic versus centralized laboratory-based Xpert MTB/RIF performance: Experience gained from a pragmatic, stepped-wedge trial in Botswana
por: Agizew, Tefera, et al.
Publicado: (2017)

The effect of sputum quality and volume on the yield of bacteriologically-confirmed TB by Xpert MTB/RIF and smear
por: Zimba, Onani, et al.
Publicado: (2019)

Systematic Review of TST Responses in People Living with HIV in Under-Resourced Settings: Implications for Isoniazid Preventive Therapy
por: Kerkhoff, Andrew D., et al.
Publicado: (2012)

Cost‐effectiveness of one month of daily isoniazid and rifapentine versus three months of weekly isoniazid and rifapentine for prevention of tuberculosis among people receiving antiretroviral therapy in Uganda
por: Ferguson, Olivia, et al.
Publicado: (2020)

Correction: Systematic Review of TST Responses in People Living with HIV in Under-Resourced Settings: Implications for Isoniazid Preventive Therapy
por: Kerkhoff, Andrew D., et al.
Publicado: (2013)

Risk scores for predicting early antiretroviral therapy mortality in sub-Saharan Africa to inform who needs intensification of care: a derivation and external validation cohort study
por: Auld, Andrew F., et al.
Publicado: (2020)

Isoniazid prophylaxis: highly effective but underutilised to prevent tuberculosis in people living with HIV
por: Vojnov, Lara, et al.
Publicado: (2022)

Isoniazid Prophylaxis for Latent Tuberculosis Infections in Liver Transplant Recipients in a Tuberculosis-Endemic Area
por: Moon, Hyung Hwan, et al.
Publicado: (2017)

Pellagra in isoniazid preventive and antiretroviral therapy
por: Kipsang, John Koech, et al.
Publicado: (2019)

Does an Isoniazid Prophylaxis Register Improve Tuberculosis Contact Management in South African Children?
por: van Soelen, Nelda, et al.
Publicado: (2013)

Tuberculosis and isoniazid prophylaxis among adult HIV positive patients on ART in Northwest Ethiopia
por: Geremew, Demeke, et al.
Publicado: (2022)

A Case of Acute Liver Failure in a Patient on Isoniazid Prophylaxis for Latent Tuberculosis
por: Philipose, Jobin, et al.
Publicado: (2022)

Derivation and external validation of a risk score for predicting HIV-associated tuberculosis to support case finding and preventive therapy scale-up: A cohort study
por: Auld, Andrew F., et al.
Publicado: (2021)

Beneficial Effect of Isoniazid Preventive Therapy and Antiretroviral Therapy on the Incidence of Tuberculosis in People Living with HIV in Ethiopia
por: Yirdaw, Kesetebirhan Delele, et al.
Publicado: (2014)

Impact of Isoniazid Resistance-Conferring Mutations on the Clinical Presentation of Isoniazid Monoresistant Tuberculosis
por: Dantes, Raymund, et al.
Publicado: (2012)

Association between 9-month isoniazid prophylaxis of latent tuberculosis and severe hepatitis in patients treated with TNF inhibitors
por: Lai, Edward Chia-Cheng, et al.
Publicado: (2021)

Treatment of isoniazid-resistant pulmonary tuberculosis
por: Kim, Yee Hyung, et al.
Publicado: (2008)

Treatment of Isoniazid-Resistant Pulmonary Tuberculosis
por: Jhun, Byung Woo, et al.
Publicado: (2020)

Expression of USP18 and IL2RA Is Increased in Individuals Receiving Latent Tuberculosis Treatment with Isoniazid
por: de Oyarzabal, Eleane, et al.
Publicado: (2019)

Empiric vs screening‐based use of isoniazid for tuberculosis prophylaxis: Safety and effectiveness in lung transplant recipients in Saudi Arabia
por: Korayem, Ghazwa B., et al.
Publicado: (2020)

Incidence of tuberculosis among PLHIV on antiretroviral therapy who initiated isoniazid preventive therapy: A multi-center retrospective cohort study
por: Kazibwe, Andrew, et al.
Publicado: (2022)

Minimum inhibitory concentrations of rifampin and isoniazid among multidrug and isoniazid resistant Mycobacterium tuberculosis in Ethiopia
por: Getahun, Muluwork, et al.
Publicado: (2022)

Isoniazid-Resistant Tuberculosis, Taiwan, 2000–2010
por: Lai, Chih-Cheng, et al.
Publicado: (2011)

Isoniazid Preventive Therapy and Risk for Resistant Tuberculosis
por: Balcells, Maria Elvira, et al.
Publicado: (2006)

Isoniazid for preventing tuberculosis in HIV‐infected children
por: Zunza, Moleen, et al.
Publicado: (2017)

Isoniazid-induced liver disorder in the treatment of tuberculosis
por: Sivannan, Srinivasan, et al.
Publicado: (2018)

Dose of Isoniazid in Renal Disease for Treatment of Tuberculosis
por: Sarma, G. R. K.
Publicado: (2022)

Implementation of a pragmatic, stepped-wedge cluster randomized trial to evaluate impact of Botswana’s Xpert MTB/RIF diagnostic algorithm on TB diagnostic sensitivity and early antiretroviral therapy mortality
por: Auld, Andrew F., et al.
Publicado: (2016)

Publisher Correction: Association between 9-month isoniazid prophylaxis of latent tuberculosis and severe hepatitis in patients treated with TNF inhibitors
por: Lai, Edward Chia‑Cheng, et al.
Publicado: (2021)

Determination of isoniazid acetylation patterns in tuberculosis patients receiving DOT therapy under the Revised National tuberculosis Control Program (RNTCP) in India
por: Imam, Faisal, et al.
Publicado: (2020)

Efficacy of isoniazid prophylactic therapy in prevention of tuberculosis in children: a meta–analysis
por: Ayieko, James, et al.
Publicado: (2014)

Isoniazid treatment for latent tuberculosis infection is tolerable for rheumatoid arthritis patients receiving tumor necrosis factor inhibitor therapy
por: Sung, Yoon-Kyoung, et al.
Publicado: (2018)

Isoniazid prophylaxis differently modulates T-cell responses to RD1-epitopes in contacts recently exposed to Mycobacterium tuberculosis: a pilot study
por: Goletti, Delia, et al.
Publicado: (2007)

Different Risk of Tuberculosis and Efficacy of Isoniazid Prophylaxis in Rheumatoid Arthritis Patients with Biologic Therapy: A Nationwide Retrospective Cohort Study in Taiwan
por: Liao, Tsai-Ling, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_23nvf4fkocr9nc7esdspi4crpo